Artiva Biotherapeutics, Inc. Common Stock (ARTV) Stock
NASDAQ · ARTV
Key stats
- Market cap
- $201.19M
- Price / Earnings ratio
- -2.0x
- EPS (TTM)
- -$2.98
- Volume
- Loading
- 52-week high
- $14.53
- 52-week low
- $2.96
Source: third-party data provider, as of November 13, 2026
Compare with ARTV
Recent news

Stocktwits
Artiva Scraps Development Of Lead Drug Candidate After Patient Deaths — ARTV Stock Heads For Worst Session In Over 18 Months
ARTVOctober 27, 2026
Stocktwits
Artiva Scraps Development Of Lead Drug Candidate After Patient Deaths — ARTV Stock Heads For Worst Session In Over 18 Months
ARTV

Zacks Investment Research
Is Artiva Biotherapeutics, Inc. (ARTV) Outperforming Other Medical Stocks This Year?
ARTVJuly 8, 2026
Zacks Investment Research
Is Artiva Biotherapeutics, Inc. (ARTV) Outperforming Other Medical Stocks This Year?
ARTV

Stocktwits
ARTV Stock Pares Majority Of Pre-Market Gains – $300M Offering Overshadows Strong Data For Rheumatoid Arthritis Therapy
ARTVMay 8, 2026
Stocktwits
ARTV Stock Pares Majority Of Pre-Market Gains – $300M Offering Overshadows Strong Data For Rheumatoid Arthritis Therapy
ARTV
Technical indicators
- RSI 14
- 22.20
- MACD 12/26/9
- -0.85
- EMA 9 of MACD
- -0.90
- MACD histogram
- 0.05
- SMA 50
- $6.95
- Price below SMA 50
- EMA 50
- $6.50
- Price below EMA 50
- SMA 200
- $8.00
- Price below SMA 200
- EMA 200
- $7.04
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Hold
Based on 3 analyst ratings
Strong Sell0
Sell0
Hold2
Buy1
Strong Buy0
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Revenue
Net income
Net margin %
2022
2023
2024
2025
40M27M13M0
Debt & Balance Sheet
Total assets
Total liabilities
2022
2023
2024
2025
251M166M83M0
Revenue to Profit
2025$0.0
Revenue$0.0
Cost of revenue$0.0
Gross profit$0.0
Operating expenses$-83.9M
Net incomeEarnings
No data available
Source: third-party data provider
Latest news

Stocktwits
Artiva Scraps Development Of Lead Drug Candidate After Patient Deaths — ARTV Stock Heads For Worst Session In Over 18 Months
ARTVOctober 27, 2026
Stocktwits
Artiva Scraps Development Of Lead Drug Candidate After Patient Deaths — ARTV Stock Heads For Worst Session In Over 18 Months
ARTV

Zacks Investment Research
Is Artiva Biotherapeutics, Inc. (ARTV) Outperforming Other Medical Stocks This Year?
ARTVJuly 8, 2026
Zacks Investment Research
Is Artiva Biotherapeutics, Inc. (ARTV) Outperforming Other Medical Stocks This Year?
ARTV

Stocktwits
ARTV Stock Pares Majority Of Pre-Market Gains – $300M Offering Overshadows Strong Data For Rheumatoid Arthritis Therapy
ARTVMay 8, 2026
Stocktwits
ARTV Stock Pares Majority Of Pre-Market Gains – $300M Offering Overshadows Strong Data For Rheumatoid Arthritis Therapy
ARTV
About Artiva Biotherapeutics, Inc. Common Stock
No description available.
SectorHealthcare
IndustryBiotechnology
Employees115
CEODr. Fred Aslan M.D.
IPO DateJul 19, 2024
HeadquartersSan Diego, CA
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Fred Aslan M.D. | CEO, Principal Financial & Accounting Officer and Director | 1975 |
| Ms. Jennifer Kinsbruner Bush Esq., J.D. | Chief Operating Officer | 1975 |
| Dr. Gines Diego Miralles M.D. | President and Head of Research & Development | 1963 |
| Mr. Christopher P. Horan | Chief Technical Operations Officer | 1967 |
| Dr. Peter Flynn Ph.D. | Co-Founder & Strategic Advisor | 1974 |
| Mr. Andrew Cronauer | VP, General Counsel & Corporate Secretary | — |
| Dr. Nicholas Veomett Ph.D. | Vice President of Corporate Development | — |
| Dr. Heather Raymon Ph.D. | Senior Vice President of Research & Early Development | 1965 |
| Dr. David Moriarty Ph.D. | Senior VP of Clinical Operations | — |
| Mr. Benjamin Dewees | Senior Vice President of Regulatory Affairs | — |
Fundamentals
Valuation
Price-to-book value0.63
Profitability
Return on Equity-45.00%
Return on Assets-41.00%
EBITDA$-95.34M
Trading
Average volume1,207,431
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 22.20
- MACD 12/26/9
- -0.85
- EMA 9 of MACD
- -0.90
- MACD histogram
- 0.05
- SMA 50
- $6.95
- Price below SMA 50
- EMA 50
- $6.50
- Price below EMA 50
- SMA 200
- $8.00
- Price below SMA 200
- EMA 200
- $7.04
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
3 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Analyst consensus:Hold
33% Buy
67% Hold
0% Sell
Analyst price target
- Low
- $4.00
- Average
- $22.00
- High
- $40.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024 | -1.7 | -0.4 | +40.3 | -34.2 | +19.2 | -20.9 | ||||||
| 2025 | -49.0 | -15.1 | -23.5 | -20.3 | -18.6 | -22.2 | +96.1 | +11.3 | -7.1 | +42.8 | -0.3 | +23.6 |
| 2026 | -8.0 | +39.2 | +11.6 | +51.7 | -26.6 | +30.0 | +3.1 | +5.0 | -36.9 | -38.3 | -2.9 |
Compare stocks
Market cap
$201.19M
-
-
-
Price / Earnings ratio
-2.00
-
-
-
Price / Sales ratio
-
-
-
Dividend yield
0.00%
-
-
-
Average volume
1,207,431
-
-
-
Earnings per share
$-2.98
-
-
-



